Clinical trials: Inflammatory Disorder
Type 2 Diabetes
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with…
- Trial name
- NCT02433678
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University at Buffalo
Nausea
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron, may help lessen or prevent nausea.
- Trial name
- NCT00475085
- Testing
- aprepitant, dexamethasone, granisetron hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 1,021 people
- Sponsor
- Joseph Roscoe
Rheumatoid Arthritis
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to…
- Trial name
- NCT01960855
- Testing
- ABT-494
- Volunteers
- 276 people
- Sponsor
- AbbVie
Ulcerative Colitis
Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis
This study aims to characterize the changes on intestinal microbiota pattern associated with the use of golimumab in order to determine if intestinal microbiota markers may correlate with golimumab therapeutic effect in patients…
- Trial name
- GOLI2015 (NCT03018925)
- Testing
- Golimumab
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Acute Kidney Injury
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
- Trial name
- STOP-AKI (NCT02182440)
- Testing
- recAP
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 301 people
- Sponsor
- AM-Pharma
Crohn's Disease
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
- Trial name
- GALAXI (NCT03466411)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 579 sites in United States, Australia and 41 more
- Volunteers
- 1,409 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis, Pouchitis
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
Intestinal ultrasound (IUS) has been studied in the evaluation of inflammatory bowel disease (IBD) and is increasingly used as a non-invasive, easy to use, cost-effective tool for point-of-care to assess disease activity and more…
- Trial name
- NCT06316999
- Testing
- Intestinal Ultrasound
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Ulcerative Colitis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis…
- Trial name
- OCTAVE (NCT01465763)
- Testing
- tofacitinib
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 614 people
- Sponsor
- Pfizer
Crohn Disease, Ulcerative Colitis
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate…
- Trial name
- NCT04877990
- Testing
- Deucravacitinib
- Where
- 43 sites in United States, Australia and 14 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
- Trial name
- NCT00724958
- Testing
- Infliximab
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to…
- Trial name
- SELECT-NEXT (NCT02675426)
- Testing
- Upadacitinib
- Where
- 167 sites in United States, Argentina and 36 more
- Volunteers
- 661 people
- Sponsor
- AbbVie
Severe Sepsis
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
- Trial name
- SAFEbt (NCT01312675)
- Testing
- S.A.F.E.BT
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- B. Braun Medical Inc.
Pain, Inflammatory
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of…
- Trial name
- NCT03485365
- Testing
- GSK3858279 IV, GSK3858279 SC
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01576367
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)
The objective of this observational study was to assess changes in fecal calprotectin levels and its suitability as a monitoring tool in participants with moderate-to-severe Crohn's Disease who were treated with adalimumab.
- Trial name
- FAIR (NCT01759264)
- Volunteers
- 101 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.
- Trial name
- NCT03269695
- Testing
- PF-06687234
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatologic Disorder, Inflammatory Bowel Diseases
Flu Vaccine Response in Patients on Biologic Therapies
This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies.
- Conditions
- Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
- Trial name
- NCT03277703
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stony Brook University
Colitis, Ulcerative, Inflammatory Bowel Disease
Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
To assess if infliximab drug levels in subjects with Ulcerative Colitis predict risk of colectomy rate. Additionally, the investigators will estimate an optimal day 4 infliximab level based on the study results.
- Conditions
- Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
- Trial name
- NCT02438410
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
This phase II trial studies how well giving accelerated radiation therapy (RT) after surgery works in treating patients with breast cancer. RT uses high energy x rays to kill tumor cells.
- Conditions
- Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma
- Trial name
- NCT01417286
- Testing
- External beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Rutgers, The State University of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.